| Nikolaus Jilg, MD | |
|
Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 | |
| (617) 726-2061 | |
| Not Available |
| Full Name | Nikolaus Jilg |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 20 Years |
| Location | Massachusetts General Hospital, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144668799 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 274873 (Massachusetts) | Primary |
| 207RI0200X | Internal Medicine - Infectious Disease | 256231 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
| The General Hospital Corporation | 6507803806 | 1054 |
News Archive
A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.
For the sixth consecutive year, global well-being improvement leader Healthways (NASDAQ: HWAY) and world-leading management consulting firm Gallup have released their analysis of the state of well-being for communities, states and congressional districts in the United States.
Researchers estimate nearly 800,000 preventable adverse drug events may occur in nursing homes each year. Many of these incidents could be prevented with safety practices such as medication reconciliation, a process in which health care professionals, such as physicians, pharmacists and nurses, review medication regimens to identify and resolve discrepancies when patients transfer between health care settings.
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
› Verified 8 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.
For the sixth consecutive year, global well-being improvement leader Healthways (NASDAQ: HWAY) and world-leading management consulting firm Gallup have released their analysis of the state of well-being for communities, states and congressional districts in the United States.
Researchers estimate nearly 800,000 preventable adverse drug events may occur in nursing homes each year. Many of these incidents could be prevented with safety practices such as medication reconciliation, a process in which health care professionals, such as physicians, pharmacists and nurses, review medication regimens to identify and resolve discrepancies when patients transfer between health care settings.
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
› Verified 8 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.
For the sixth consecutive year, global well-being improvement leader Healthways (NASDAQ: HWAY) and world-leading management consulting firm Gallup have released their analysis of the state of well-being for communities, states and congressional districts in the United States.
Researchers estimate nearly 800,000 preventable adverse drug events may occur in nursing homes each year. Many of these incidents could be prevented with safety practices such as medication reconciliation, a process in which health care professionals, such as physicians, pharmacists and nurses, review medication regimens to identify and resolve discrepancies when patients transfer between health care settings.
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
› Verified 8 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.
For the sixth consecutive year, global well-being improvement leader Healthways (NASDAQ: HWAY) and world-leading management consulting firm Gallup have released their analysis of the state of well-being for communities, states and congressional districts in the United States.
Researchers estimate nearly 800,000 preventable adverse drug events may occur in nursing homes each year. Many of these incidents could be prevented with safety practices such as medication reconciliation, a process in which health care professionals, such as physicians, pharmacists and nurses, review medication regimens to identify and resolve discrepancies when patients transfer between health care settings.
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nikolaus Jilg, MD Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Ph: (617) 726-2061 | Nikolaus Jilg, MD Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Ph: (617) 726-2061 |
News Archive
A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.
For the sixth consecutive year, global well-being improvement leader Healthways (NASDAQ: HWAY) and world-leading management consulting firm Gallup have released their analysis of the state of well-being for communities, states and congressional districts in the United States.
Researchers estimate nearly 800,000 preventable adverse drug events may occur in nursing homes each year. Many of these incidents could be prevented with safety practices such as medication reconciliation, a process in which health care professionals, such as physicians, pharmacists and nurses, review medication regimens to identify and resolve discrepancies when patients transfer between health care settings.
Hillenbrand reported third quarter 2010 revenue of $205.8 million, a $47.1 million (30 percent) increase over the prior year, due primarily to the inclusion of revenue generated by K-Tron International, which Hillenbrand acquired April 1, 2010. Business acquisition costs and the impact of purchase accounting were the primary drivers of a $12.1 million (48 percent) decrease in net income from the prior year and a $0.19 (46 percent) decrease in earnings per share, from $0.41 to $0.22.
› Verified 8 days ago
Kaitlyn My-tu Lam, MBBS Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |